The size of the European Enteral Feeding Devices Market was worth USD 0.62 billion in 2022. It is estimated to be growing at a CAGR of 5.24% and worth USD 0.80 billion by 2027.
Enteral feeding devices are essential for people suffering from medical ailments such as swallowing disorders, digestive disorders, neurological disorders, cancer, and others.
The growing aging population suffering from various chronic diseases across the European region is one of the key factors propelling the European enteral feeding devices market growth. A considerable amount of the European population is suffering from chronic diseases such as neurological disorders, stroke, and diabetes, and the number of people suffering from these diseases is estimated to grow in the coming years. According to the data published by the World Economic Forum, an estimated 30% of the European population is expected to be aged 65 years by 2100. The growing incidence of chronic diseases can be attributed to the growing adoption of unhealthy diets, increasing consumption of alcohol and smoking, lack of physical activity, and others. Furthermore, with increasing age, most older people suffer from progressive dementia disorder. Patients with advanced dementia suffer from difficulties in swallowing, which reduces the nutritional intake in the body. It also changes the functioning appetite and apraxia. Therefore, these people use enter feeding devices to recover fast from the illness.
The growing incidence of premature births is another major factor driving the European enteral feeding devices market growth. For instance, approximately 500,000 babies are born prematurely in Europe yearly, which is majorly due to mothers suffering from obesity and diabetes, and several other complications. These premature babies have lightweight, and some of the internal organs are in the developing stage. As a result, to avoid complications in the future for premature babies. These eternal food devices are inserted through the mouth or nose to send sufficient nutrients to the baby for complete growth.
The growing prevalence of head and neck cancer in the European region is anticipated to aid the market growth during the forecast period. However, patients suffering from head and neck cancer frequently lack nutrition due to continuous chemotherapy to stop cancer growth. This chemotherapy results in loss of taste, fatigue, nausea, and vomiting. As a result, to recover from malnutrition, enter tube feeding is used by the patens, which helps to recover from the illness.
Furthermore, the growing adoption of technological developments in manufacturing advanced enteral feeding devices is estimated to fuel the market’s growth rate. The growing focus of the European region's key market participants to manufacture portable enteral feeding devices is significantly favoring the regional market. Due to growing cases of tube mistakes when placing them in the lungs, the manufacturers have designed a device named DoubleCHEK which helps clinicians and carers place nasogastric feeding tubes safely.
However, the high cost of advanced enteral feeding devices is limiting the market growth in the European region. In addition, usability issues associated with enteral feeding devices, such as misplacement of the enteral feeding tube into the body, hamper the adoption of these devices and negatively impact the market growth in Europe. Furthermore, the need for more advanced infrastructure in hospitals, lack of skilled professionals, and lack of reimbursement policies in some European countries are expected to hinder the growth rate of the European enteral feeding devices market.
This research report on the European enteral feeding devices market has been segmented and sub-segmented into the following categories:
By Product Type:
Based on product type, the enteral feeding pump segment captured the major share of the European market in 2021, and the domination of the segment is anticipated to continue during the forecast period.
Based on stage, the pediatric segment is expected to play a leading role in the European market in the coming years.
Based on application, the oncology segment had the major share of the European market in 2021.
By End User:
Based on end-user, the hospital segment led the market in 2021. However, the ambulatory care services segment is expected to register the fastest CAGR in the coming years.
Geographically, the European market is forecasted to experience promising growth in the coming years owing to the increasing prevalence of infectious and chronic diseases such as cancer and diabetes. The growing aging population is expected to fuel the enteral feeding devices market in Europe. An estimated 65% of the aged people are suffering from at least one chronic disease in the European population. Due to this, enteral nutrition demand has rapidly increased. It is estimated that 35% of all European patients suffer from malnutrition.
Royal Numico NV, Novartis AG, Fresenius Kabi AG, Nestlé, and Abbott Laboratories Ltd are notable European enteral food market players. Worldwide, Abbott Laboratories Ltd is number one in this market due to its presence in the United States. Novartis AG is second. Abbott Laboratories Ltd, Novartis AG, and Royal Numico NV are all located in Eastern Europe. Northern Europe is a large and well-established market (Germany, the United Kingdom, and the Netherlands). Although these countries are not developing as fast, it is necessary that companies can continue to grow in stable markets. It is where the growth potential is essential. Per capita consumption in Germany, the United Kingdom, and the Netherlands are the highest. Southern Europe is a rapidly growing market (France, Spain, and Italy). They have displayed growth over the past four to five years. Surfacing markets in Eastern Europe are much more trivial but show higher growth.
Strict remuneration regulations across the healthcare spectrum in Europe are likely to harm the incorporation of enteral foods by hospitals. However, adequate reimbursement, especially in the growing home care sector, aims to boost the enteral feeding product adoption. Furthermore, reimbursement regulations, such as the legislation in force in Germany in October 2015, have reduced illnesses/conditions for patients entitled to reimbursable enteral nutrition (28 illnesses down to 5). Consequently, hospital activity and investments, and innovations in this field by manufacturers are negatively affected.
The UK market had the dominating share of the European market in 2021. In Europe, the usage of enteral tube feeding has been increasing gradually in the last few years. According to the United Kingdom survey, nearly 40,000 adult and pediatric patients require home enteral feeding to supplement nutrition in the body. The government has provided several guidelines for approving feeding devices to feed sufficient nutrition to patients, which helps for fast recovery.
During the forecast period, the German market is anticipated to showcase the fastest CAGR owing to the growing number of enteral feeding device manufacturers, which has further led to the development of cost-effective eternal feeding devices. In addition, the increasing number of awareness programs regarding the usage of eternal feeding devices by the key market players is expected to boost the German market growth. Furthermore, favorable reimbursement policies for enteral feeding device treatment are expected to promote the growth rate of the European market.
KEY MARKET PLAYERS:
Companies playing a notable role in the Europe enteral feeding devices market profiled in this report are Halyard Health Inc., C. R. Bard, Inc., Abbott Laboratories, Fresenius SE, Covidien PLC, Cook Medical, and Nestle S.A.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com